Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (.sup.165Ho) and dysprosium-164 (.sup.164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).

Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (.sup.165Ho) and dysprosium-164 (.sup.164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).

A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12.

A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12.

A threefold decrease in α-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A and Mix B applied together with VitaminD+K2 shows significant effect on increased insulin secretion and glucose uptake by cells.

A threefold decrease in α-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A and Mix B applied together with VitaminD+K2 shows significant effect on increased insulin secretion and glucose uptake by cells.

A threefold decrease in α-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A and Mix B applied together with VitaminD+K2 shows significant effect on increased insulin secretion and glucose uptake by cells.

The present invention provides a composition comprising an acidified aqueous solution of (1) micro colloidal silicic acid, (2) boric acid, and (3) a water absorbing additive, having a pH value of equal to or less than 1, wherein the micro colloidal silicic acid has particle sizes in the range of 1-8 nm, especially in the range of 1.5-6 nm. The invention also provides a particulate product obtainable by the method according to claim 18, wherein the particles comprise (1) silicic acid, (2) boric acid, and (3) the water absorbing additive, and wherein at least 90% of the particles in the particulate product have particle sizes in the range of 0.3-5 μm.

The present invention provides a composition comprising an acidified aqueous solution of (1) micro colloidal silicic acid, (2) boric acid, and (3) a water absorbing additive, having a pH value of equal to or less than 1, wherein the micro colloidal silicic acid has particle sizes in the range of 1-8 nm, especially in the range of 1.5-6 nm. The invention also provides a particulate product obtainable by the method according to claim 18, wherein the particles comprise (1) silicic acid, (2) boric acid, and (3) the water absorbing additive, and wherein at least 90% of the particles in the particulate product have particle sizes in the range of 0.3-5 μm.

A method for treating or preventing saccharide-related diseases or disorders, comprising administering a therapeutically or prophylactically effective amount of a polymer comprising at least one boronic acid group to a subject having or at risk of having a saccharide-related disease or disorder.